In CRC, downregulation of poly C-binding protein 1 (PCIF1) increases the sensitivity of CRC tumors to anti-PD-1 therapy by regulating the Fos-Tgf-β and Stat1/Ifitm3-IFN-γ axes (Wang L. et al., 2023). This evidence concerns the gene TGFB1 and colorectal carcinoma.